DDInter740 DDInter1293
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Flecainide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Nilotinib
Flecainide {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Flecainide {u} (Compound) causes {v} (Side Effect) Anxiety
Anxiety {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Flecainide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nilotinib
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Flecainide {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Flecainide {u} (Compound) causes {v} (Side Effect) Anxiety
Anxiety {u} (Side Effect) is caused by {v} (Compound) Raltegravir
Raltegravir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nilotinib
Flecainide {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Flecainide {u} (Compound) causes {v} (Side Effect) Photophobia
Photophobia {u} (Side Effect) is caused by {v} (Compound) Oxcarbazepine
Oxcarbazepine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Flecainide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound)
Flecainide (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Nilotinib (Compound)
Flecainide (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may lead to a major life threatening interaction when taken with Nilotinib
Flecainide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Flecainide (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is upregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Flecainide (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Raltegravir (Compound) and Raltegravir may cause a minor interaction that can limit clinical effects when taken with Nilotinib
Flecainide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Flecainide (Compound) causes Photophobia (Side Effect) and Photophobia (Side Effect) is caused by Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib